ZCA
HAE icon

Zeke Capital Advisors’s Haemonetics HAE Stock Holding History

Zeke Capital Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,326
Closed -$612K – 352
2019
Q4 		$612K Hold
5,326
– – 0.05% 334
2019
Q3 		$672K Sell
5,326
-437
-8% -$55.5K 0.06% 291
2019
Q2 		$694K Hold
5,763
– – 0.07% 276
2019
Q1 		$504K Sell
5,763
-5,847
-50% -$532K 0.05% 355
2018
Q4 		$1.16M Buy
11,610
+5,159
+80% +$542K 0.11% 174
2018
Q3 		$739K Buy
6,451
+3,727
+137% +$386K 0.06% 307
2018
Q2 		$244K Buy
+2,724
New +$230K 0.02% 477

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Zeke Capital Advisors's HAE Position: Q1 2020 in Review

Zeke Capital Advisors sold out of Haemonetics (HAE) in Q1 2020, closing a stake of 5,326 shares — an estimated $612K sold.

Zeke Capital Advisors first reported a position in HAE in Q2 2018 and held it in 7 quarters. The position peaked at $1.16M in Q4 2018. 269 funds tracked by Wall St. Rank hold HAE as of Q1 2020.

  • Zeke Capital Advisors reported no remaining Haemonetics position as of Q1 2020 after selling out during the quarter.
  • Zeke Capital Advisors sold 5,326 Haemonetics shares in Q1 2020, an estimated $612K.
  • Zeke Capital Advisors first reported a position in Haemonetics in Q2 2018 and held it in 7 quarters.
  • Zeke Capital Advisors's Haemonetics position peaked at $1.16M in Q4 2018.
  • 269 funds tracked by Wall St. Rank held Haemonetics as of Q1 2020.

Based on Zeke Capital Advisors's 13F filing for Q1 2020, filed 24 Apr 2020.